search
Back to results

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Primary Purpose

Breast Cancer Nos Metastatic Recurrent

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ad-RTS-hIL-12 and Veledimex
Palifosfamide
Sponsored by
Alaunos Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer Nos Metastatic Recurrent focused on measuring Genetically Modified Organism, Metastatic Breast Cancer, Recurrent Breast Cancer, Breast Cancer, Palifosfamide, INXN1001, INXN2001, Adenoviral vector

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Males or females ≥ 18 years of age
  2. Histologically or cytologically confirmed adenocarcinoma of the breast, either locally recurrent or metastatic disease with injectable lesions, for which no proven curative therapy exists.
  3. Failed or progressed on at least 1 prior systemic chemotherapy regimen ± biologic/experimental therapy (if first-line therapy, failure or progression during the first 30 days).
  4. Resolution of all treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy ≤ Grade 2 and alopecia.
  5. A minimum of 2 lesion(s) assessed by imaging using mRECIST v1.1.
  6. Eastern Cooperative Oncology Group performance status 0, 1, 2
  7. Male and female subjects must agree to use a highly reliable method of birth control.
  8. Adequate bone marrow reserve as indicated by:

    1. Absolute neutrophil count > 1500/μL (without use of growth factors within 7 days)
    2. Absolute lymphocyte count > 700/μL (without use of growth factors within 7 days)
    3. Platelet count > 100,000/mm3 (without transfusion in prior 7 days)
    4. Hemoglobin > 9.0 g/dL (without transfusion in prior 7 days)
  9. Estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation: eGFR ≥ 60 mL/min/1.73 m2
  10. Adequate liver function as evidenced by the following:

    1. Bilirubin ≤ 1.5 times the upper limits of normal (ULN)
    2. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 2.5×ULN, in the case of liver metastases ≤ 5×ULN

Exclusion Criteria:

  1. Subjects with human epidermal growth factor receptor 2 (HER2)/neu-positive (immunohistochemistry [IHC]) 3+ or fluorescence in situ hybridization-amplified) breast tumors who are eligible for, but who have not received HER2-targeted therapy (eg, trastuzumab)
  2. Concomitant anticancer therapies
  3. Prior therapies discontinuation periods:

    1. Radiation within 3 weeks of enrollment
    2. Chemotherapy within 4 weeks of enrollment
    3. Nitrosoureas within 6 weeks of enrollment
    4. Biologic therapy and/or immunomodulatory therapy, checkpoint inhibitors within 6 weeks of enrollment
    5. No washout period is required for endocrine therapy
  4. Radiation therapy encompassing >25% of bone marrow
  5. History of bone marrow or stem cell transplantation
  6. Any congenital or acquired condition leading to inability to generate an immune response
  7. Immunosuppressive therapy:

    1. Systemic immunosuppressive drugs including corticosteroids (prednisone equivalent >10 mg/day)
    2. Immune suppression/requiring immunosuppressive drugs, including organ allografts
    3. Active autoimmune disease requiring the equivalent of >10 mg/day of prednisone
  8. Major surgery within 4 weeks of study treatment
  9. History of prior malignancy, unless the prior malignancy was diagnosed and definitively treated ≥5 years previously with no subsequent evidence of recurrence
  10. Subjects with brain or subdural metastases, unless local therapy has completed and corticosteroids have been discontinued for this indication for ≥4 weeks before starting study treatment.
  11. Any medications that induce, inhibit, or are substrates of cytochrome P450 (CYP450) 3A4 within 7 days prior to the first dose of study drug
  12. Subjects with meningeal carcinomatosis
  13. Known significant hypersensitivity to study drugs or excipients
  14. History of malabsorption syndrome or other condition that would interfere with enteral absorption
  15. International Normalized Ratio (INR) and activated partial thromboplastin time [PTT] <1.5 x ULN, if not therapeutically anticoagulated.
  16. New York Heart Association (NYHA) Class II or greater congestive heart failure OR active ventricular arrhythmia requiring medication
  17. Any other unstable or clinically significant concurrent medical condition
  18. Localized infection at site of injectable lesion(s) requiring antiinfective therapy within 2 weeks of the first dose of study drug.

Sites / Locations

  • Baptist Cancer Institute
  • Henry Ford Health System
  • Billings Clinic
  • Signal Point Clinical Research Center
  • Greenville Hospital System
  • The Jones Clinic, PC
  • Mary Crowley Medical Research Center
  • Evergreen Hematology & Oncology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Ad-RTS-hIL-12 and veledimex

Ad-RTS-hIL-12 and Palifosfamide

Arm Description

Experimental study drug monotherapy arm (A)

Study drug combination therapy arm (C)

Outcomes

Primary Outcome Measures

Safety and tolerability of study drug therapy based on type and rate of adverse events and 16-week PFS rate.

Secondary Outcome Measures

Objective response rate (ORR) by modified RECIST v1.1
Proportion of subjects achieving a confirmed PR or CR according to modified RECIST v1.1
Clinical Benefit rate: proportion of subjects with CR, PR, or SD by modified RECIST v1.1
Estimate PFS by modified RECIST v1.1
Evaluate Pharmacodynamic tumor markers in tumor tissue samples that may correlate with objective tumor response and/or clinical outcome

Full Information

First Posted
August 29, 2012
Last Updated
January 26, 2015
Sponsor
Alaunos Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT01703754
Brief Title
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Official Title
A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alaunos Therapeutics

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions. Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with chemotherapy (palifosfamide) is safe and efficacious.
Detailed Description
Multicenter, open-label, randomized study evaluating the safety and efficacy of INXN-1001 (veledimex) and INXN-2001 (Ad-RTS-hIL-12) alone and in combination with palifosfamide. Part 1 is the safety run-in where a safety assessment will be made after 1 cycle of therapy. Part 2, eligible subjects will be randomly assigned to active treatment Arms A or C. Once the monotherapy (Arm A) is determined to be safe and tolerable, Part 1 combination therapy (Arm C) will begin. Subjects should receive six cycles of study treatment, in the absence of meeting withdrawal criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer Nos Metastatic Recurrent
Keywords
Genetically Modified Organism, Metastatic Breast Cancer, Recurrent Breast Cancer, Breast Cancer, Palifosfamide, INXN1001, INXN2001, Adenoviral vector

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ad-RTS-hIL-12 and veledimex
Arm Type
Experimental
Arm Description
Experimental study drug monotherapy arm (A)
Arm Title
Ad-RTS-hIL-12 and Palifosfamide
Arm Type
Experimental
Arm Description
Study drug combination therapy arm (C)
Intervention Type
Genetic
Intervention Name(s)
Ad-RTS-hIL-12 and Veledimex
Other Intervention Name(s)
Adenoviral Vector, Oral activator ligand
Intervention Description
Oral activator ligand with adenoviral vector injection of cancer lesions
Intervention Type
Drug
Intervention Name(s)
Palifosfamide
Other Intervention Name(s)
Pali
Intervention Description
Small molecule chemotherapy, IV administration
Primary Outcome Measure Information:
Title
Safety and tolerability of study drug therapy based on type and rate of adverse events and 16-week PFS rate.
Time Frame
Approximately 24 weeks-Beginning from the time a patient signs the informed consent to the Follow up Tumor Assessment visit
Secondary Outcome Measure Information:
Title
Objective response rate (ORR) by modified RECIST v1.1
Description
Proportion of subjects achieving a confirmed PR or CR according to modified RECIST v1.1
Time Frame
Approximately 24 weeks- From first study drug dose to Follow-Up Tumor Assessment Visit
Title
Clinical Benefit rate: proportion of subjects with CR, PR, or SD by modified RECIST v1.1
Time Frame
Approximately 24 weeks
Title
Estimate PFS by modified RECIST v1.1
Time Frame
Approximately 24 weeks, beginning at the first study drug administratrion and ending at the Follow up Tumor Assessment visit
Title
Evaluate Pharmacodynamic tumor markers in tumor tissue samples that may correlate with objective tumor response and/or clinical outcome
Time Frame
Approximately 24 weeks, starting with first study drug administrationa and ending at the Follow up Tumor Assessment visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Males or females ≥ 18 years of age Histologically or cytologically confirmed adenocarcinoma of the breast, either locally recurrent or metastatic disease with injectable lesions, for which no proven curative therapy exists. Failed or progressed on at least 1 prior systemic chemotherapy regimen ± biologic/experimental therapy (if first-line therapy, failure or progression during the first 30 days). Resolution of all treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy ≤ Grade 2 and alopecia. A minimum of 2 lesion(s) assessed by imaging using mRECIST v1.1. Eastern Cooperative Oncology Group performance status 0, 1, 2 Male and female subjects must agree to use a highly reliable method of birth control. Adequate bone marrow reserve as indicated by: Absolute neutrophil count > 1500/μL (without use of growth factors within 7 days) Absolute lymphocyte count > 700/μL (without use of growth factors within 7 days) Platelet count > 100,000/mm3 (without transfusion in prior 7 days) Hemoglobin > 9.0 g/dL (without transfusion in prior 7 days) Estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation: eGFR ≥ 60 mL/min/1.73 m2 Adequate liver function as evidenced by the following: Bilirubin ≤ 1.5 times the upper limits of normal (ULN) Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 2.5×ULN, in the case of liver metastases ≤ 5×ULN Exclusion Criteria: Subjects with human epidermal growth factor receptor 2 (HER2)/neu-positive (immunohistochemistry [IHC]) 3+ or fluorescence in situ hybridization-amplified) breast tumors who are eligible for, but who have not received HER2-targeted therapy (eg, trastuzumab) Concomitant anticancer therapies Prior therapies discontinuation periods: Radiation within 3 weeks of enrollment Chemotherapy within 4 weeks of enrollment Nitrosoureas within 6 weeks of enrollment Biologic therapy and/or immunomodulatory therapy, checkpoint inhibitors within 6 weeks of enrollment No washout period is required for endocrine therapy Radiation therapy encompassing >25% of bone marrow History of bone marrow or stem cell transplantation Any congenital or acquired condition leading to inability to generate an immune response Immunosuppressive therapy: Systemic immunosuppressive drugs including corticosteroids (prednisone equivalent >10 mg/day) Immune suppression/requiring immunosuppressive drugs, including organ allografts Active autoimmune disease requiring the equivalent of >10 mg/day of prednisone Major surgery within 4 weeks of study treatment History of prior malignancy, unless the prior malignancy was diagnosed and definitively treated ≥5 years previously with no subsequent evidence of recurrence Subjects with brain or subdural metastases, unless local therapy has completed and corticosteroids have been discontinued for this indication for ≥4 weeks before starting study treatment. Any medications that induce, inhibit, or are substrates of cytochrome P450 (CYP450) 3A4 within 7 days prior to the first dose of study drug Subjects with meningeal carcinomatosis Known significant hypersensitivity to study drugs or excipients History of malabsorption syndrome or other condition that would interfere with enteral absorption International Normalized Ratio (INR) and activated partial thromboplastin time [PTT] <1.5 x ULN, if not therapeutically anticoagulated. New York Heart Association (NYHA) Class II or greater congestive heart failure OR active ventricular arrhythmia requiring medication Any other unstable or clinically significant concurrent medical condition Localized infection at site of injectable lesion(s) requiring antiinfective therapy within 2 weeks of the first dose of study drug.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francois Lebel, MD
Organizational Affiliation
Ziopharm Oncology
Official's Role
Study Director
Facility Information:
Facility Name
Baptist Cancer Institute
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Billings Clinic
City
Billings
State/Province
Montana
ZIP/Postal Code
59101
Country
United States
Facility Name
Signal Point Clinical Research Center
City
Middletown
State/Province
Ohio
ZIP/Postal Code
45042
Country
United States
Facility Name
Greenville Hospital System
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
The Jones Clinic, PC
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Mary Crowley Medical Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75201
Country
United States
Facility Name
Evergreen Hematology & Oncology
City
Spokane
State/Province
Washington
ZIP/Postal Code
99218
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

We'll reach out to this number within 24 hrs